HK1069413A1 - Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene - Google Patents

Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene

Info

Publication number
HK1069413A1
HK1069413A1 HK05102010.7A HK05102010A HK1069413A1 HK 1069413 A1 HK1069413 A1 HK 1069413A1 HK 05102010 A HK05102010 A HK 05102010A HK 1069413 A1 HK1069413 A1 HK 1069413A1
Authority
HK
Hong Kong
Prior art keywords
polymorphisms
methods
cntf gene
treating psychosis
schizophrenia based
Prior art date
Application number
HK05102010.7A
Other languages
English (en)
Inventor
Sridhar Kudaravalli
Mihael Hristos Polymeropoulos
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1069413A1 publication Critical patent/HK1069413A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia
HK05102010.7A 2001-12-10 2005-03-08 Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene HK1069413A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33983501P 2001-12-10 2001-12-10
PCT/EP2002/013937 WO2003054226A2 (en) 2001-12-10 2002-12-09 Methods of treating psychosis and schizophrenia based on a polymorphism in the ctf gene

Publications (1)

Publication Number Publication Date
HK1069413A1 true HK1069413A1 (en) 2005-05-20

Family

ID=23330814

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05102010.7A HK1069413A1 (en) 2001-12-10 2005-03-08 Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene

Country Status (16)

Country Link
US (3) US20050059006A1 (xx)
EP (1) EP1458888B1 (xx)
JP (2) JP2005512576A (xx)
CN (1) CN1612941B (xx)
AT (1) ATE503845T1 (xx)
AU (1) AU2002358110A1 (xx)
BR (1) BRPI0214821B8 (xx)
CA (1) CA2468972A1 (xx)
CY (1) CY1111594T1 (xx)
DE (1) DE60239634D1 (xx)
DK (1) DK1458888T3 (xx)
ES (1) ES2364037T3 (xx)
HK (1) HK1069413A1 (xx)
PT (1) PT1458888E (xx)
SI (1) SI1458888T1 (xx)
WO (1) WO2003054226A2 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2364037T3 (es) 2001-12-10 2011-08-23 Novartis Ag Métodos de tratamiento de psicosis y esquizofrenia basados en polimorfismos del gen del cntf.
ES2825949T3 (es) 2004-09-30 2021-05-17 Vanda Pharmaceuticals Inc Métodos para administrar iloperidona
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
MX2008014843A (es) 2006-05-22 2008-12-05 Vanda Pharmaceuticals Inc Tratamiento de trastornos depresivos.
WO2008060400A2 (en) * 2006-11-15 2008-05-22 Sirtris Pharmaceuticals, Inc. Sirtuin polymorphisms and methods of use thereof
US9080214B2 (en) 2007-05-18 2015-07-14 Vanda Pharmaceuticals, Inc. Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
US8652776B2 (en) * 2007-09-10 2014-02-18 Vanda Pharmaceuticals, Inc. Prediction of QT prolongation based on SNP genotype
US9328387B2 (en) 2007-09-10 2016-05-03 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on SNP genotype
MX2010006520A (es) 2007-12-13 2010-11-30 Vanda Pharmaceuticals Inc Metodo y composicion para el tratamiento de una condicion mediada por alfa-adrenoceptor.
EP2222300B1 (en) 2007-12-13 2014-06-11 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
EP2514840B1 (en) * 2008-01-02 2014-10-22 Suregene Llc Genetic markers of mental illness, in particular in the ASTN2 gene
EP2581454B1 (en) * 2008-01-17 2015-09-16 Suregene LLC Genetic markers of mental illness
US20100144781A1 (en) * 2008-10-29 2010-06-10 Dong-Jing Fu Methods of treating psychosis and schizophrenia based on polymorphisms in the erbb4 gene
ES2533091T3 (es) 2009-05-15 2015-04-07 Vanda Pharmaceuticals Inc. Tratamiento antipsicótico basado en genotipo de SNP de DRD2 o ANKK1
US10874659B2 (en) 2012-03-14 2020-12-29 Vanda Pharmaceuticals Inc. Iloperidone metabolite for use in the treatment of psychiatric disorders
US10877498B2 (en) * 2017-10-27 2020-12-29 Brasscraft Manufacturing Company Excess flow and thermal valve
US20210319849A1 (en) * 2018-08-28 2021-10-14 Koninklijke Philips N.V. Method for assessing genome alignment basis
US11214827B2 (en) * 2018-08-30 2022-01-04 Vanda Pharmaceuticals Inc. Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
WO2020216832A1 (en) * 2019-04-24 2020-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the response of antipsychotic drugs
CN110184345B (zh) * 2019-07-11 2020-05-05 南京先声医学检验有限公司 用于检测精神及神经类疾病用药相关snp位点的引物组、应用、产品及方法
CN111187829A (zh) * 2020-02-24 2020-05-22 内蒙古医科大学 Lp基因启动子区甲基化检测引物与检测方法及其应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4478832A (en) * 1982-06-28 1984-10-23 Chevron Research Company Pesticidal O-(N-alkoxy-substituted-benzimidoyl)-phosphorus esters and thioesters
US5610035A (en) * 1983-12-05 1997-03-11 Institut Pasteur Centre National De La Recherche Scientific Methods for the preparation of hybridomas producing lymphadenopathy-associated virus (LAV) GP110-specific monoclonal antibodies and methods for the purification of GP110 employing said monoclonal antibodies
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4843155A (en) * 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
AU624601B2 (en) 1988-01-21 1992-06-18 Genentech Inc. Amplification and detection of nucleic acid sequences
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
WO1989010414A1 (en) 1988-04-28 1989-11-02 Robert Bruce Wallace AMPLIFIED SEQUENCE POLYMORPHISMS (ASPs)
US5130238A (en) * 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
JP2955759B2 (ja) 1988-07-20 1999-10-04 セゲブ・ダイアグノスティックス・インコーポレイテッド 核酸配列を増幅及び検出する方法
DK0457824T4 (da) 1989-02-13 2004-10-11 Geneco Pty Ltd Detektion af en nukleinsyresekvens eller en ændring deri
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5302509A (en) * 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US5169766A (en) * 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5846717A (en) * 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
IL103267A (en) * 1991-09-24 2004-07-25 Keygene Nv Process and kit for amplification of restriction fragment obtained from starting dna
ATE198358T1 (de) 1992-04-27 2001-01-15 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5605798A (en) * 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5610053A (en) * 1993-04-07 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
JPH09507121A (ja) 1993-10-26 1997-07-22 アフィマックス テクノロジーズ ナームロゼ ベノートスハップ 生物学的チップ上の核酸プローブアレー
IL108159A (en) 1993-12-23 1998-02-08 Orgenics Ltd Apparatus for separation, concentration and detection of target molecules in liquid sample
ATE247716T1 (de) * 1994-02-07 2003-09-15 Beckman Coulter Inc Ligase/polymerase-vermittelte analyse genetischer elemente von einzelnukleotid-polymorphismen und ihre verwendung in der genetischen analyse
US5578832A (en) * 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5539083A (en) * 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5556752A (en) * 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5854033A (en) * 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5866404A (en) * 1995-12-06 1999-02-02 Yale University Yeast-bacteria shuttle vector
US5945283A (en) * 1995-12-18 1999-08-31 Washington University Methods and kits for nucleic acid analysis using fluorescence resonance energy transfer
CA2267070A1 (en) 1996-11-06 1998-05-14 Sequenom, Inc. Compositions and methods for immobilizing nucleic acids to solid supports
CA2702219C (en) 1996-11-06 2013-01-08 Sequenom, Inc. High density immobilization of nucleic acids
JP2003516111A (ja) * 1999-02-22 2003-05-13 バリアジェニックス インコーポレーテッド 疾病の治療法の決定において有用性を有する遺伝子配列変異
US20040171056A1 (en) 1999-02-22 2004-09-02 Variagenics, Inc., A Delaware Corporation Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
JP2000346828A (ja) * 1999-06-02 2000-12-15 Hitachi Ltd 電気泳動装置
DE1233365T1 (de) 1999-06-25 2003-03-20 Genaissance Pharmaceuticals Verfahren zur herstellung und verwendung von Haplotype Daten
EP1206943B1 (en) * 1999-08-26 2010-04-07 Takeda Pharmaceutical Company Limited Matrix adhering to nasal mucosa
JP4632499B2 (ja) * 1999-08-26 2011-02-16 武田薬品工業株式会社 鼻粘膜付着マトリックス
JP3324594B2 (ja) * 1999-12-20 2002-09-17 株式会社日立製作所 バイオ製品の品質保証方法及びバイオ情報の配信方法
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
ES2364037T3 (es) * 2001-12-10 2011-08-23 Novartis Ag Métodos de tratamiento de psicosis y esquizofrenia basados en polimorfismos del gen del cntf.
AU2003302442A1 (en) 2002-11-25 2004-06-18 Michael Leslie Harris Multi flush toilet cistern
US7851069B2 (en) 2005-11-18 2010-12-14 Federal Mogul World-Wide, Inc. Heat shield with integral attachment flanges

Also Published As

Publication number Publication date
BRPI0214821B1 (pt) 2015-07-07
US8460867B2 (en) 2013-06-11
US20090239908A1 (en) 2009-09-24
ATE503845T1 (de) 2011-04-15
EP1458888A2 (en) 2004-09-22
JP2005512576A (ja) 2005-05-12
BR0214821A (pt) 2004-11-03
DK1458888T3 (da) 2011-06-20
ES2364037T3 (es) 2011-08-23
US20080027106A1 (en) 2008-01-31
CN1612941B (zh) 2011-11-16
EP1458888B1 (en) 2011-03-30
JP2011006422A (ja) 2011-01-13
CN1612941A (zh) 2005-05-04
US20050059006A1 (en) 2005-03-17
AU2002358110A8 (en) 2003-07-09
WO2003054226A3 (en) 2004-04-01
CY1111594T1 (el) 2015-10-07
CA2468972A1 (en) 2003-07-03
SI1458888T1 (sl) 2011-07-29
AU2002358110A1 (en) 2003-07-09
PT1458888E (pt) 2011-06-01
JP5785697B2 (ja) 2015-09-30
DE60239634D1 (de) 2011-05-12
BRPI0214821B8 (pt) 2021-07-27
WO2003054226A2 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
HK1069413A1 (en) Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene
BG66289B1 (en) Combination of epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases
PT1572095E (pt) Β-l-2'-desoxinucleósidos para tratamento de estirpes resistentes de vhb
SE9900100D0 (sv) New compounds
DK0876818T3 (da) Middel til behnadling af nerodegenerative lidelser
GB0117645D0 (en) Therapeutic stratergies for prevention and treatment of alzheimers disease
AU2003284968A8 (en) Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
HUP0402629A3 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2003038123A3 (en) Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
HK1023293A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
AU2002308778A1 (en) Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
PL371464A1 (en) 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them
WO2002102297A3 (en) Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders
PL369763A1 (en) Heterocyclic compounds for use in the treatment of disorders of the urinary tract
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
HK1080408B (zh) 溴莫尼定在治療痴呆和帕金森病中的用途
HK1040908A1 (en) Use of optically pure (R)-tofisopam for treating and preventing anxiety disorders.
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2002364945A8 (en) Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
AU2002358580A1 (en) Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determing single nucleotide polymorphisms
AU2003285482A1 (en) Methods and means for the treatment of inflammatory disorders involving genotyping of the 5, 10- methylenetetrahydrofolate reductase (mthfr) gene
MXPA04001309A (es) Uso de sps o mch-r para identificar desordenes geneticos al mantener el peso corporal normal.
HUP0202416A3 (en) Novel pharmaceutical combination and it's use for the treatment of certain cardiovascular disorders
AU2003298547A8 (en) 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety
MXPA04001001A (es) PRAMIPEXOL PARA EL TRATAMIENTO DEL TRASTORNO DE HIPERACTIVIDAD Y DeFICIT DE LA ATENCION.

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20221208